Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$23.83

-0.88 (-3.56%)

05:21
02/14/19
02/14
05:21
02/14/19
05:21

Aimmune should be bought on any weakness from NEJM letter, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond tells investors to buy shares of Aimmune Therapeutics on any weakness after a letter to the editor published in this week's New England Journal of Medicine questioned the safety of AR101. The analyst views the letter as "clearly biased" and notes it "purposely" conflates AR101 with "unrelated, and irrelevant" oral immunotherapy approaches. Moreover, a little digging shows the author of the letter has ownership interest in Prota Therapeutics, an oral immunotherapy competitor to AR101, which "should have received more consideration by NEJM reviewers in the first place," Raymond tells investors in a research note. "That this bias was seemingly ignored, allowing a clearly misleading letter such as this to be published raises what we see as serious questions regarding NEJMs editorial process," adds the analyst. As such, he views the letter as "nothing more than noise." Raymond keeps an Overweight rating on Aimmune with a $60 price target.

  • 22

    Feb

AIMT Aimmune
$23.83

-0.88 (-3.56%)

01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
01/15/19
PIPR
01/15/19
NO CHANGE
Target $60
PIPR
Overweight
Aimmune FDA delay does not change bullish thesis, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says the FDA review delay for Aimmune Therapeutics' AR101 due to the government shutdown does not change bullish thesis on the shares. In a research note titled "Trump Shutdown Claims its First Biotech Victim (That We Know Of)," Raymond, while admitting that there is clearly no end in sight to the current shutdown, urges investor patience with respect to Aimmune shares as the "fundamental story has not changed." He keeps an Overweight rating on the shares with a $60 price target.
01/18/19
JMPS
01/18/19
NO CHANGE
Target $40
JMPS
Outperform
JMP pushes out launch assumptions for Aimmune's AR101 due to FDA uncertainty
JMP Securities analyst Liisa Bayko noted that the FDA has told Aimmune that it will not begin the review of the BLA for AR101 due to the government shutdown, but also because AR101 is an allergenic product. Beyond the shutdown impact, this action by the FDA, or lack thereof, highlights that AR101 may be exempt from PDUFA, meaning there is no firm commitment to items such as Priority Review, Bayko said. Given this new level of uncertainty, she has pushed back her U.S. launch projection for AR101 to 2020 from late 2019, but since she has also pushed back concurrent launch expenses the delay has no material impact on her valuation, Bayko stated. She keeps an Outperform rating and $40 price target on Aimmune shares.
02/11/19
STFL
02/11/19
NO CHANGE
Target $25
STFL
Hold
Stifel stays cautious on emerging peanut immunotherapy category
Stifel analyst Derek Archila said he remains cautious on long-term revenue opportunities for Aimmune's (AIMT) AR101 and DBV Technologies' (DBVT) Viaskin peanut and on the emerging peanut immunotherapy category. Childrens' adherence to medications has been challenging across many severe and chronic indications and he does not think peanut allergy treatments will buck the trend, Archila tells investors. After lowering his sales forecasts due to more conservative assumptions about adherence, Archila cut his price target on Aimmune to $25 from $33 and lowered his price target on DBV shares to $10 from $11. He maintains Hold ratings on both stocks.

TODAY'S FREE FLY STORIES

BDRBF

Bombardier

$0.00

(0.00%)

11:05
02/22/19
02/22
11:05
02/22/19
11:05
Hot Stocks
Bombardier to invest $22M in two aerospace research projects in Quebec »

Bombardier announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZG

Zillow

$40.94

5.87 (16.74%)

, Z

Zillow

$41.12

6.09 (17.39%)

11:03
02/22/19
02/22
11:03
02/22/19
11:03
Hot Stocks
Zillow adds to gain as Citron sets $70 target, turns positive after CEO change »

Shares of Zillow Group…

ZG

Zillow

$40.94

5.87 (16.74%)

Z

Zillow

$41.12

6.09 (17.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

BECN

Beacon Roofing

$37.50

0.13 (0.35%)

11:02
02/22/19
02/22
11:02
02/22/19
11:02
Hot Stocks
Beacon Roofing announces departure of CEO Paul Isabella later this year »

Beacon Roofing Supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

C

Citi

$64.03

-0.28 (-0.44%)

11:00
02/22/19
02/22
11:00
02/22/19
11:00
Options
Active trading in Citigroup short-term puts »

Active trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Apr

  • 28

    May

  • 13

    Jul

ZG

Zillow

$40.54

5.47 (15.60%)

, Z

Zillow

$40.94

5.91 (16.87%)

10:57
02/22/19
02/22
10:57
02/22/19
10:57
Periodicals
Citron says now positive on Zillow, calls returning CEO a 'stud' »

Citron Research tweeted:…

ZG

Zillow

$40.54

5.47 (15.60%)

Z

Zillow

$40.94

5.91 (16.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

ZG

Zillow

$40.54

5.47 (15.60%)

, Z

Zillow

$40.94

5.91 (16.87%)

10:57
02/22/19
02/22
10:57
02/22/19
10:57
Periodicals
Breaking Periodicals news story on Zillow, Zillow »

Citron Research turns…

ZG

Zillow

$40.54

5.47 (15.60%)

Z

Zillow

$40.94

5.91 (16.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

PFE

Pfizer

$43.02

0.88 (2.09%)

10:55
02/22/19
02/22
10:55
02/22/19
10:55
Periodicals
Pfizer exec to host presidential fundraiser for Gillibrand campaign, CNBC says »

Pfizer's executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 18

    May

PLNT

Planet Fitness

$59.40

1.14 (1.96%)

10:50
02/22/19
02/22
10:50
02/22/19
10:50
Options
Earnings hedge opened in Planet Fitness »

Earnings hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

FDX

FedEx

$178.46

-3.82 (-2.10%)

, AMZN

Amazon.com

$1,625.63

5.79 (0.36%)

10:44
02/22/19
02/22
10:44
02/22/19
10:44
On The Fly
Stamps.com plummets after announcing discontinuation of USPS partnership »

Shares of Stamps.com…

FDX

FedEx

$178.46

-3.82 (-2.10%)

AMZN

Amazon.com

$1,625.63

5.79 (0.36%)

STMP

Stamps.com

$84.82

-113.26 (-57.18%)

UPS

UPS

$109.32

-2.44 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 18

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

TROX

Tronox

$11.80

0.45 (3.96%)

10:40
02/22/19
02/22
10:40
02/22/19
10:40
Options
Bullish call flow in Tronox ahead of earnings next week »

Bullish call flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

10:40
02/22/19
02/22
10:40
02/22/19
10:40
General news
Fed's Williams: the Phillips Curve is "alive and well" »

Fed's Williams: the…

C

Citi

$64.24

-0.07 (-0.11%)

, INTC

Intel

$52.73

1.33 (2.59%)

10:39
02/22/19
02/22
10:39
02/22/19
10:39
On The Fly
Citi, Intel upgrades, Roku, Nordstrom downgrades among today's top analyst calls »

Check out today's top…

C

Citi

$64.24

-0.07 (-0.11%)

INTC

Intel

$52.73

1.33 (2.59%)

ROKU

Roku

$59.51

8.04 (15.62%)

JWN

Nordstrom

$43.50

-0.97 (-2.18%)

KHC

Kraft Heinz

$34.95

-13.24 (-27.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

  • 06

    Mar

  • 25

    Mar

  • 26

    Mar

  • 15

    Apr

  • 28

    May

  • 13

    Jul

EA

Electronic Arts

$93.86

-2.97 (-3.07%)

10:37
02/22/19
02/22
10:37
02/22/19
10:37
Periodicals
EA starts massive round of layoffs at Australian studio, Kotaku reports »

Electronic Arts has begun…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

PYX

Pyxus

$24.70

-1.46 (-5.58%)

10:36
02/22/19
02/22
10:36
02/22/19
10:36
Initiation
Pyxus initiated  »

Pyxus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$31.60

0.26 (0.83%)

10:30
02/22/19
02/22
10:30
02/22/19
10:30
Options
Downside hedge opened in Xerox April options »

Downside hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$149.39

32.25 (27.53%)

10:29
02/22/19
02/22
10:29
02/22/19
10:29
Recommendations
Wayfair analyst commentary  »

Wayfair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 03

    Mar

10:26
02/22/19
02/22
10:26
02/22/19
10:26
General news
Stocks higher as trade talks continue »

Stock futures were higher…

ACER

Acer Therapeutics

$24.25

0.38 (1.59%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Jun

AVEO

Aveo Pharmaceuticals

$0.62

0.0006 (0.10%)

, BMY

Bristol-Myers

$50.47

0.32 (0.64%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
Piper Jaffray biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

AVEO

Aveo Pharmaceuticals

$0.62

0.0006 (0.10%)

BMY

Bristol-Myers

$50.47

0.32 (0.64%)

EXEL

Exelixis

$21.28

0.06 (0.28%)

IMMU

Immunomedics

$14.34

0.01 (0.07%)

JNJ

Johnson & Johnson

$135.83

0.43 (0.32%)

MRK

Merck

$80.55

0.73 (0.91%)

NKTR

Nektar

$40.10

-0.16 (-0.40%)

PFE

Pfizer

$42.89

0.75 (1.78%)

SGEN

Seattle Genetics

$69.99

0.74 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 11

    Apr

  • 18

    May

  • 20

    May

  • 17

    Jun

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
Cowen consumer analysts to hold an analyst/industry conference call »

Consumer Analysts Kernan…

XEC

Cimarex Energy

$73.78

0.45 (0.61%)

, REN

Resolute Energy

$31.93

0.41 (1.30%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
Resolute Energy to host special shareholder meeting »

Special Shareholder…

XEC

Cimarex Energy

$73.78

0.45 (0.61%)

REN

Resolute Energy

$31.93

0.41 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 04

    Mar

  • 22

    May

LKSD

LSC Communications

$9.20

-0.21 (-2.23%)

, QUAD

Quad/Graphics

$15.63

-0.165 (-1.04%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
Quad/Graphics to host special shareholder meeting »

Special Shareholder…

LKSD

LSC Communications

$9.20

-0.21 (-2.23%)

QUAD

Quad/Graphics

$15.63

-0.165 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

QUAD

Quad/Graphics

$15.63

-0.165 (-1.04%)

, LKSD

LSC Communications

$9.20

-0.21 (-2.23%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
LSC Communications to host special shareholder meeting »

Special Shareholder…

QUAD

Quad/Graphics

$15.63

-0.165 (-1.04%)

LKSD

LSC Communications

$9.20

-0.21 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

ELGX

Endologix

$0.54

0.0223 (4.27%)

10:25
02/22/19
02/22
10:25
02/22/19
10:25
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

ACAM

Acamar Partners

$0.00

(0.00%)

10:23
02/22/19
02/22
10:23
02/22/19
10:23
Syndicate
Acamar Partners opens at $10.01, IPO priced at $10.00 per share »

Acamar Partners (ACAM)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.